No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T20:53:36.012Z. Latest historical point 2026-03-31. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Whitehawk Therapeutics Inc (WHWK) stock was $3.61 as of Oct 6, 2026, 4:00 PM EDT, down 2.43% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +88.2% · 3-year avg -5.4%/yr · 5-year avg -33.1%/yr
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer.
Biotechnology · Morristown, NJ
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-0.26
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.20
vs Estimate
$-0.26
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1WHWK | $205.80M | $3.61 | -2.43% | +88.20% | -33.13% | N/A | N/A |
| 2PDEX | $207.27M | $64.92 | -0.74% | +91.61% | +20.45% | +31.26% | vs WHWK |
| 3ETRA | $208.31M | $9.82 | +0.82% | N/A | N/A | N/A | vs WHWK |
| 4CGEN | $209.91M | $2.22 | -3.90% | +41.48% | -18.39% | -9.42% | vs WHWK |
| 5TRDA | $210.41M | $5.42 | -1.09% | -8.63% | N/A | N/A | vs WHWK |
| 6ALEC | $200.96M | $1.81 | -9.05% | -39.91% | -39.17% | N/A | vs WHWK |
forward FY estimate
N/A
$0.00
vs Estimate
$-350000.00
Consensus Rating
Based on 7 analysts
Average Price Target
$7.71
+113.7% upside
Low
$4.00
Current
$3.61
High
$10.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.30 | $-0.22 | $-0.17 | 4 |
| Quarter ending Dec 2026 | $-0.30 | $-0.21 | $-0.11 | 4 |
| Quarter ending Mar 2027 | $-0.22 | $-0.22 | $-0.22 | 1 |
| Quarter ending Jun 2027 | $-0.23 | $-0.23 | $-0.23 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.21 | $-0.95 | $-0.75 | 5 |
| FY 2027 | $-0.96 | $-0.89 | $-0.77 | 5 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $8.83M | $8.83M | $8.83M | 9 |
| FY 2027 | $10.91M | $10.91M | $10.91M | 8 |
